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Dystrophin deficiency, which leads to severe and progressive muscle degeneration in patients with Duchenne mus-
cular dystrophy (DMD), is caused by frameshifting mutations in the dystrophin gene. A relatively new therapeutic
strategy is based on antisense oligonucleotides (AONs) that induce the specific skipping of a single exon, such that
the reading frame is restored. This allows the synthesis of a largely functional dystrophin, associated with a milder
Becker muscular dystrophy phenotype. We have previously successfully targeted 20 different DMD exons that
would, theoretically, be beneficial for 175% of all patients. To further enlarge this proportion, we here studied the
feasibility of double and multiexon skipping. Using a combination of AONs, double skipping of exon 43 and 44
was induced, and dystrophin synthesis was restored in myotubes from one patient affected by a nonsense mutation
in exon 43. For another patient, with an exon 46–50 deletion, the therapeutic double skipping of exon 45 and 51
was achieved. Remarkably, in control myotubes, the latter combination of AONs caused the skipping of the entire
stretch of exons from 45 through 51. This in-frame multiexon skipping would be therapeutic for a series of patients
carrying different DMD-causing mutations. In fact, we here demonstrate its feasibility in myotubes from a patient
with an exon 48–50 deletion. The application of multiexon skipping may provide a more uniform methodology
for a larger group of patients with DMD.
Introduction
Antisense oligonucleotides (AONs) have recently be-
come an attractive tool for the study and treatment of
human disease. Initially, AONs were used for the se-
quence-specific inhibition of genes, either to elucidate
developmental processes or to suppress malignant or ab-
errant gene expression (Dennis et al. 1998; Stevenson et
al. 1999; Nasevicius and Ekker 2000; Corey and Abrams
2001; Dove 2002). In these studies, AONs mediated
RNAse H degradation of dsRNA, or they blocked tran-
scription or translation initiation. However, AONs are
also capable of modulating the splicing of pre-mRNA
(Sierakowska et al. 1996). Since it has been estimated
that at least 15% of disease-causing point mutations result
in RNA splicing defects (Krawczak et al. 1992; Cartegni
et al. 2002; Buratti et al. 2003), this latter application
may be highly relevant for future genetic therapies. For
instance, RNAse H-resistant AONs have successfullybeen
used to induce the skipping of pseudo-exons by blocking
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cryptic splice sites in the b-globin gene (Sierakowska et
al. 1996) and the cystic fibrosis transmembrane conduc-
tance regulator gene (Friedman et al. 1999). Alterna-
tively, AONs linked to 10 arginine-serine dipeptide re-
peats for the artificial recruitment of splicing enhancer
factors have been applied in vitro to induce inclusion of
mutated BRCA1 and SMN2 exons that otherwise would
be skipped (Cartegni and Krainer 2003). AONs have
also been effective in altering the ratio of alternative
splicing, which was applied for cancer-related genes to
direct malignant toward nonmalignant isoforms (Mer-
catante et al. 2001, 2002). Last, but not least, a prom-
ising, recently developed application of AONs is to in-
duce the specific skipping of exons in order to correct
the reading frame of a mutated transcript so that it can
be translated into a partially functional protein. The
DMD gene, which codes for dystrophin, is well suited
for this latter application. The protein consists of an N-
terminal domain that binds to actin filaments, a central
rod domain, and a C-terminal cysteine-rich domain that
binds to the dystrophin-glycoprotein complex (Hoffman
et al. 1987; Koenig et al. 1988; Yoshida and Ozawa
1990). Mutations in the DMD gene that interrupt the
reading frame result in a complete loss of dystrophin
function, which causes the severe Duchenne muscular
dystrophy (DMD [MIM 310200]) (Hoffman et al. 1988;
Koenig et al. 1989; Ervasti et al. 1990). The milder
Becker muscular dystrophy (BMD [MIM 300376]), on
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Figure 1 Schematic overview of double and multiexon skipping in three patients with and one human control. AONs are indicated by
blue lines. Primers for RT-PCR analysis are indicated by arrows. A, Patient DL90.3 has a nonsense mutation in exon 43 (indicated by an
asterisk). The resulting out-of-frame transcript is indicated in red. In contrast to single-exon skipping of exon 43 or 44, double-exon skipping
of both exons restores the reading frame (in-frame transcript indicated in green). When myotubes derived from this patient are targeted by
AONs specific for exons 43 and 44, single-exon skipping of exon 43 and exon 44 (indicated by red dotted lines) can be expected in addition
to the anticipated double-exon skipping. Patient DL470.2 carries an exon 46–50 deletion, which results in a frameshift and a stop codon in
exon 51. Single-exon skipping of exon 45 or exon 51 is not frame restoring, whereas double-exon skipping of both exons 45 and 51 is. B,
Multiexon skipping of exons 45–51 preserves the reading frame in a control transcript (individual KM109). Patient 50685.1 has a deletion of
exons 48–50, resulting in a stop codon in exon 51. Multiexon skipping of exons 45, 46, 47, and 51 restores the reading frame for this patient.
In addition to the skipping of exons 45–51, single-exon skipping of exon 45 and exon 51 can also be expected.
the other hand, is the result of mutations in the same
gene that are not frameshifting and result in an internally
deleted but partially functional dystrophin that has re-
tained its N- and C-terminal ends (Koenig et al. 1989;
Di Blasi et al. 1996). Over two-thirds of patients with
DMD and BMD have a deletion of 1 exon (den Dun-
nen et al. 1989). Remarkably, patients have been de-
scribed who exhibit very mild BMD and who lack up
to 67% of the central rod domain (England et al. 1990;
Winnard et al. 1993; Mirabella et al. 1998). This sug-
gests that, despite large deletions, a partially functional
dystrophin can be generated, provided that the deletions
render the transcript in frame.
These observations have led to the idea of using
AONs to alter splicing so that the open reading frame
is restored and the severe DMD phenotype is converted
into a milder BMD phenotype. Several studies have
shown therapeutic AON-induced single-exon skipping
in cells derived from the mdx mouse model (Dunckley
et al. 1998; Wilton et al. 1999; Mann et al. 2001, 2002;
Lu et al. 2003) and various DMD patients (Takeshima
et al. 2001; van Deutekom et al. 2001; Aartsma-Rus et
al. 2002, 2003; De Angelis et al. 2002). To date, we
have identified a series of AONs that can be used to
induce the skipping of 20 different exons (exons 2, 8,
17, 19, 29, 40–46, 48–53, 55, and 59) (Aartsma-Rus
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et al. 2002). Of all patients with DMD, 175% would
benefit from the skipping of these exons. So far, we have
successfully applied single-exon skipping in cells derived
from eight different patients with DMD (van Deutekom
et al. 2001; Aartsma-Rus et al. 2003). In these studies,
the skipping of exons flanking out-of-frame deletions
or an in-frame exon containing a nonsense mutation
restored the reading frame and induced the synthesis of
BMD-like dystrophins in ∼75%–80% of treated cells.
These novel dystrophins could be detected as early as
16 h after transfection; the dystrophins increased to sig-
nificant levels within 4 d and were maintained for at
least 7 d (Aartsma-Rus et al. 2003).
Here, we significantly extend the therapeutic appli-
cability of this technique by demonstrating double and
multiexon skipping (fig. 1). Following the simultaneous
skipping of two exons (double-exon skipping), the read-
ing frame was restored for one patient with a nonsense
mutation in an out-of-frame exon and for another pa-
tient with a deletion that could not be bypassed by the
skipping of only one exon. Furthermore, through the
skipping of an entire stretch of consecutive exons (mul-
tiexon skipping), a BMD-like deletion was generated
with the potential to restore up to 14% of all known
DMD mutations.
Material and Methods
AONs and Primers
Exon-internal AONs targeting exons 44 (h44AON1)
and 51 (h51AON2) were described elsewhere (Aartsma-
Rus et al. 2002). The AONs targeting exons 43 and 45
were specifically designed for this study (h43AON5:
CUGUAGCUUCACCCUUUCC; h45AON5: GCCCA-
AUGCCAUCCUGG). BLAST analysis of the AONs did
not reveal perfect homology to other sequences in the
human genome (maximum homology 94%, minimum
E value 0.3). All AONs contain a 5′ fluorescein group
(6-FAM), a full-length phosphorothioate backbone, and
2′-O-methyl–modified ribose molecules (Eurogentec). To
avoid interference with the fluorescent signals of the sec-
ondary antibodies, unlabeled AONs were used for im-
munohistochemical analyses. Primers for RT-PCR anal-
ysis (fig. 1) were synthesized by Eurogentec (sequences
available upon request).
Myogenic Cell Cultures and AON Transfections
Primary myoblasts from a human control and from
two patients with DMD (DL470.2 [exon 46–50 dele-
tion] and 50685.1 [exon 48–50 deletion]) were isolated
from a muscle biopsy and cultured as described else-
where (Aartsma-Rus et al. 2002). Myotubes were ob-
tained from confluent myoblast cultures, after 7–14 d
of serum deprivation. These were transfected with
mixtures of 200 nM of each AON. Polyethylenemine
(PEI) was used as transfection reagent, according to the
manufacturer’s instructions (ExGen 500 [Fermentas]).
Separate AON-PEI dilutions were made for each AON,
with 3.5 ml PEI applied per mg of transfected AON.
For patient DL90.3, who has a point mutation in exon
43, only fibroblasts were available. Following infection
(multiplicity of infection [MOI] 50–100) with an ade-
noviral vector containing the MyoD gene (Ad50MyoD),
the fibroblasts were forced into myogenesis, according
to protocols described elsewhere (Murry et al. 1996;
Roest et al. 1996; Aartsma-Rus et al. 2002; Havenga et
al. 2002). Transfection conditions were identical to those
described above.
RNA Isolation and RT-PCR Analysis of the Skip
Products
RNA isolation, RT-PCR, and sequence analysis were
performed as described elsewhere (Aartsma-Rus et al.
2002). See figure 1 for the location of the primers. For
quantification of the skip products, nested PCRs were
performed using 24 cycles. PCR products were analyzed
using the DNA 1000 LabChip kit and the 2100 Bioan-
alyzer (Agilent Technologies).
To analyze the splicing of the entire DMD gene, RT
reactions were performed with 1 mg RNA, random hex-
amer primers, and SuperScript III (Invitrogen). PCR
analyses were performed using the protein-truncation
test (PTT) primers described elsewhere (Roest et al.
1993). Since some of the PCR primers were located in
exons that were deleted for patient DL470.2, we spe-
cifically designed additional primers in exons 41, 42, 45,
53, and 54 (sequences available on request).
Analysis of the Dystrophin Protein
Immunohistochemical and Western blot analyses were
performed as described elsewhere (Aartsma-Rus et al.
2002). Myosin polyclonal antibody L53 (a gift from Dr.
M. van den Hoff, Amsterdam Medical Center, The Neth-
erlands) was used to detect myosin. MANDYS1 (a gift
from Dr. G. Morris, North East Wales Institute, United
Kingdom), NCL-DYS2 (Novacastra Laboratories), and
NCL-DYS1 (Novacastra Laboratories) were used to de-
tect dystrophin. For the Western blot analysis, dystro-
phin levels were quantified using LumiAnalyst 3.0
(Roche).
Results
Double-Exon Skipping in Two Patients with DMD
The skipping of only a single exon is not sufficient to
restore the reading frame for every mutation. In a sig-
nificant fraction of mutations, it is necessary to skip two
exons simultaneously (fig. 1A). For instance, patient
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Figure 2 Double-exon skipping in patient DL90.3, who carries a nonsense mutation in the out-of-frame exon 43. A, RT-PCR analysis
of dystrophin mRNA fragments in AON-treated myotube cultures showed a shorter, novel transcript not present in nontransfected (NT) myotube
cultures. Sequence analysis confirmed the precise skipping of both exon 43 and exon 44. Along with the double skip, we also detected a single
skip of exon 44 but not a single-exon skip of exon 43. Note that weak additional fragments, slightly shorter than the wild-type products, were
present. These were derived from heteroduplex formation. 100 bpp size marker; RT-PCRp negative control. B, Immunohistochemical analysis
of the AON-treated myotube cultures. Cells were stained for myosin to identify fully differentiated myotubes (lower panel). Monoclonalantibodies
MANDYS1 and Dys2 were used to detect dystrophin 2 d after transfection. No dystrophin signals could be detected in untreated cells stained
with MANDYS1 (left panel) or Dys2 (not shown), whereas clear dystrophin signals could be detected in treated cells for both dystrophin
antibodies. Magnification # 63. C, Western blot analysis of the AON-treated myotube cultures. The monoclonal antibody Dys1 was used to
detect dystrophin. Protein extracts isolated from MyoD-transduced human control (HC) fibroblasts were used as a positive control. To avoid
overexposure, this sample was diluted 1:5. To confirm equal loading of protein samples, blots were additionally stained with an antibody against
myosin. No dystrophin was detected in NT myotube cultures. Clear dystrophin signals were observed in AON-treated myotube cultures after
2 d, which were increased at 4 d.
DL90.3 carries a nonsense mutation in exon 43. Con-
sidering that this single exon is out of frame, the skipping
of exon 43 removes the nonsense mutation but does not
restore the reading frame. Since the combination of ex-
ons 43 and 44 is in frame, we aimed at the simultaneous
skipping of both exons. Patient DL470.2 is affected by
a deletion of exons 46–50. Frame restoration requires
the joint skipping of the two exons flanking the deletion
(fig. 1A).
Myotube cultures from these patients were transfected
with a mixture of either exon 43– and 44–specific AONs
(patient DL90.3) or exon 45– and 51–specific AONs
(patient DL470.2). Transfection efficiencies were typi-
cally 180%, as indicated by the number of cells with
specific nuclear uptake of fluorescent AONs. RT-PCR
analysis at 24 or 48 h after transfection indeed dem-
onstrated the feasibility of specific double-exon skipping
in both patients (30% and 75% of total transcript frag-
ments for patients DL90.3 and DL470.2, respectively),
which was confirmed by sequence analysis (figs. 2A and
3A). As expected, in addition to double-exon skipping,
we also detected single-exon skipping in patient DL90.3
(exon 44; 27% of total transcripts) and patient DL470.2
(exon 51; 12% of total transcripts).
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Figure 3 Double-exon skipping in patient DL470.2, who carries a deletion of exons 46–50. A, RT-PCR analysis of dystrophin mRNA
fragments of AON-treated myotube cultures showed a shorter, novel transcript not present in NT myotube cultures. The precise skipping of
both exon 45 and exon 51 was confirmed by sequence analysis. Along with the double skip, we also detected a single skip of exon 51 but no
single skip of exon 45. Because of heteroduplex formation, we observed weak additional fragments, slightly shorter than the wild-type products.
100 bpp size marker; RT-PCRp negative control. B, Immunohistochemical analysis of the AON-treated myotube cultures. Cells were stained
for myosin to identify fully differentiated myotubes (lower panel). Monoclonal antibodies MANDYS1 and Dys2 were used to detect dystrophin
2 d after transfection. In treated cells, clear dystrophin signals could be detected for both antibodies, in contrast to untreated cells stained with
MANDYS1 (left panel) or Dys2 (not shown). Magnification# 63. C, Western blot analysis of the AON-treated myotube cultures. Monoclonal
antibody Dys1 was used to detect dystrophin. Protein extracts isolated from human control myotubes were used as a positive control, which
was diluted 1:10 to avoid overexposure. Blots were additionally stained with an antibody against myosin to confirm equal loading of all samples.
No dystrophin was detected in NT myotube cultures, whereas clear dystrophin signals were observed in AON-treated myotube cultures after
1 d, which increased after 2 d. Note that the dystrophin from patient DL470.2 is shorter than the control dystrophin. This correlates with the
size of the deletion.
To verify that no larger or other regions of the DMD
transcript were affected by the AON treatments, we per-
formed RT-PCR analysis on the entire DMD gene, with
consecutive sets of exons. In both treated and untreated
myotubes, we did not detect additional aberrant splicing
patterns in the DMD gene (fig. 4).
Immunohistochemical analysis using two different an-
tibodies directed against internal (MANDYS1) and C-
terminal (Dys2) parts of dystrophin showed that the in-
frame transcripts derived from double-exon skipping
produced BMD-like dystrophins. On average, 70% of the
myosin-positive myotubes showed dystrophin expression
in response to AON transfection (figs. 2B and 3B). West-
ern blot analysis confirmed the presence of dystrophin for
patient DL90.3 (after 4 d) and patient DL470.2 (after 2
d), at levels of 3.3% and 1.8%, respectively, when com-
pared to control myotubes (figs. 2C and 3C).
Multiexon Skipping
The splicing of exon 44 directly to exon 52 (as induced
in patient DL470.2) generates an in-frame transcript.
Inducing the skipping of this entire stretch of exons—
that is, multiexon skipping—would generate a BMD-
like deletion (exons 45–51) spanning a range of smaller,
internal DMD mutations (fig. 1B). Multiexon skipping
was first tested in human control myotubes (individual
KM109) treated with a mixture of 200 nM of both the
exon 45– and 51–specific AONs (fig. 5A). We observed
a novel, shorter transcript, corresponding to a size that
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Figure 4 RT-PCR analysis of the entire DMD transcript from
RNA, isolated from untreated () and treated () myotubes from
both patients. The anticipated specific-exon skipping patterns are pre-
sent in the fragments containing exons 34–45 (patient DL90.3) and
42–53 (patients DL90.3 and DL470.2). Note that because of the de-
letion of exons 46–50, the wild-type fragment for this patient is shorter
than that of patient DL90.3. No unexpected splicing anomalies were
detected in other parts of the DMD gene, confirming the sequence
specificity of the AONs. “M” is the 100-bp size marker.
would result from the targeted skipping of exons 45–
51. Indeed, sequence analysis revealed that exon 44 was
directly spliced to exon 52 (data not shown). We then
applied it to myotubes derived from a patient with DMD
(50685.1) carrying an exon 48–50 deletion (fig. 1B). The
AON-induced skipping of all exons from 45 to 51
yielded the intended in-frame transcript (fig. 5A).
Double and Multiexon Skipping Using a U-Linked
Combination of AONs
The skipping of more than one exon from one pre-
mRNA molecule requires both AONs to be present in
the same nucleus, targeting the same molecule. To spe-
cifically enhance this probability, we designed a com-
bined AON containing both the exon 45 and 51 AONs
(h45AON5 and h51AON2), linked by 10 uracil nucle-
otides (fig. 5B). After transfection of this “U-linked
AON” into myotubes from the human control (individ-
ual KM109) and the two patients with DMD (DL470.2
and 50685.1), RT-PCR analysis demonstrated its effi-
cacy to generate the in-frame transcript with exon 44
spliced to exon 52 (fig. 5A). This multiexon skipping
occurred specifically and precisely at the exon bound-
aries, as confirmed by sequence analysis (data not
shown). Quantification showed that the U-linked AON
was more efficient than the mixture of AONs in myo-
tubes from patient 50685.1 and the human control but
not in myotubes from patient DL470.2 (fig. 5C).
Discussion
Antisense-induced skipping of a single exon has shown
therapeutic potential to correct the reading frame and
induce the synthesis of BMD-like dystrophins in cultured
muscle cells from patients with DMD (Takeshima et al.
2001; van Deutekom et al. 2001; De Angelis et al. 2002;
Aartsma-Rus et al. 2003). Here, we demonstrate the
feasibility of targeted antisense-induced multiexon skip-
ping for therapeutic purposes. The spontaneous skipping
of multiple exons frequently occurs in nature, albeit at
low levels. This has been detected both in patients with
DMD and in unaffected individuals (Sironi et al. 2002).
Furthermore, this phenomenon has been suggested to be
the underlying mechanism for the occurrence of dystro-
phin-positive “revertant” fibers in the mdx mouse model
and in patients with DMD (Sherratt et al. 1993; Thanh
et al. 1995; Lu et al. 2000). Multiexon skipping has also
been observed in DMD gene-therapy studies aimed at
the targeted skipping of the mutated exon 23 in mdx
mouse muscle cells (Dunckley et al. 1998; Wilton et al.
1999; Bertoni et al. 2003). Both AONs and chimeric
DNA-RNA oligonucleotides directed at the 3′ splice site
of this exon generated shorter in-frame or out-of-frame
transcripts in which additional exons adjacent to exon
23 were skipped. In this study, we specifically focused
on inducing multiexon skipping. By use of combinations
of AONs, the double skipping of exons 43–44 and 45–
51 was induced in patient-derived myotube cultures. Im-
munohistochemical analysis of single myotubes indi-
cated that this allowed the synthesis of dystrophins in
up to 70% of myotubes. This percentage is not signif-
icantly lower than those obtained in our previous single-
exon–skipping studies (75%–80%) (Aartsma-Rus et al.
2003). This suggests that both the transfection and the
skipping performance of two AONs simultaneously are
not significantly less efficient than those of a single AON.
However, in a number of the remaining dystrophin-neg-
ative myotubes only single-exon skipping occurred.
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Figure 5 Double and multiexon skipping in myotubes from the human control (individual KM109) and from patients DL470.2 (deletion
of exons 46–50) and 50685.1 (deletion of exons 48–50). A, RT-PCR analysis of dystrophin mRNA fragments in myotube cultures treated with
either a mixture of h45AON5 and h51AON2 (mix) or a U-linked combination of these AONs (U). In all samples treated with either the mixture
of AONs or the U-linked AON, a shorter transcript fragment was detected that contained exon 44 precisely spliced to exon 52 (confirmed by
sequence analysis; data not shown). This was not present in NT myotubes. The novel in-frame transcript arose from double-exon skipping in
patient DL470.2 (the targeted exons 45 and 51 are flanking the deletion), but in both the control and patient 50685.1 the transcript was a
result of multiexon skipping. Also observed were additional shorter fragments, which were caused by single-exon skipping (exon 45 or 51) or
partial multiexon skipping (exons 46–51). Note that in some lanes, other fragments, slightly shorter than the wild-type products, were present.
This was a result of heteroduplex formation. 100 bpp size marker; RT-PCR p negative control. B, Schematic drawing of the U-linked AON.
The exon 51–specific AON (h51AON2) is linked to the exon 45–specific AON (h45AON5) by 10 uracil nucleotides. C, All fragments were
quantified using the DNA 1000 LabChip and the Bioanalyzer (Agilent). The percentage of double or multiexon skipping of exons 45–51 was
determined by the ratio of this fragment to the total of transcript fragments. In contrast to patient DL470.2, the U-linked AON was more
efficient for patients KM109 and 50685.1, when compared to the mixture of individual AONs.
Western blot analysis of protein extracts from patient-
derived total myotube cultures showed relatively low
levels (3%) of dystrophin. Considering the high levels
(70%) observed in the immunohistochemical analysis,
there seems to be a discrepancy. However, this can be
explained by the fact that in the immunohistochemical
analysis we focus on single myosin-positive myotubes,
whereas the samples in the Western blot analysis also
include a significant number of dystrophin-negative
cells. Furthermore, the control protein sample was de-
rived from a culture that exhibited a two-fold higher
degree of myogenicity (i.e., ∼40% in the patient cultures
vs. 190% in the control sample) and that accordingly
contained a higher number of dystrophin-producing
cells. Finally, the control protein sample in the Western
blot analysis was derived from myotubes expressing
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dystrophin over the entire period of differentiation (2
wk), whereas in the patient-derived myotubes the dys-
trophin synthesis was only just induced at the time of
analysis (at most, 4 d). Since myotubes are viable for
only several days after transfection, longer expression
periods were unachievable.
Different ratios of exon 45– and 51–specific AONs
were evaluated, and the highest levels of double-exon
skipping were obtained with a 1:1 ratio (data not
shown). Both AONs were apparently equally efficient
at entering the nucleus. Besides double-exon skipping,
we also observed single-exon skipping of exon 44 (pa-
tient DL90.3) and exon 51 (patient DL470.2), in par-
ticular. This suggests that the local secondary pre-
mRNA structure was probably more affected by AONs
targeting these exons, which subsequently rendered ex-
ons 43 and 45 inaccessible.
To increase the probability not only that both AONs
are taken up by the same nucleus but also that they
hybridize to the same RNA molecule, we designed an
AON that consisted of two AONs linked with 10 uracil
nucleotides. Compared to the mixture of the two AONs,
the U-linked AON indeed induced higher levels of mul-
tiexon skipping in myotubes from a human control and
a patient carrying an exon 48–50 deletion. In contrast,
for yet-unknown reasons it was less efficient in inducing
double-exon skipping in myotubes from a patient car-
rying an exon 46–50 deletion. In follow-up studies, we
assessed the influence of the length of the U-linker. We
did not observe significant differences (data not shown).
There are two possible explanations for the mechanism
of multiexon skipping. First, the entire region of both
exons and introns between exon 45 and 51 may have
been spliced out because of an overall AON-induced
alteration in the secondary structure of the pre-mRNA.
Second, the splicing of the individual exons 45 through
51 may have occurred earlier than that of exon 44 to
exon 45 (which is not unlikely, given that intron 44 is
270 kb long). In that case, the splicing machinery re-
garded exons 45 to 51 as one large exon and omitted
it because of the AONs that hybridized to exons 45 and
51. The latter explanation suggests that multiexon skip-
ping may only be effective in those areas of the DMD
gene in which downstream introns are spliced prior to
upstream introns. We are currently verifying this by us-
ing different combinations of (U-linked) AONs in other
regions of the gene.
When only single-exon skipping is taken into ac-
count, the antisense-based reading frame correction
therapy would theoretically be beneficial for 175% of
all patients with DMD. Multiexon skipping would sig-
nificantly extend this percentage to most DMD muta-
tions, except those that affect the functionally critical
domains of the N-terminus or the cysteine-rich C-ter-
minal domain, or those that involve the promoter re-
gion, the first exon, or translocations. However, these
latter mutations are found in !8% of all patients with
DMD reported in our database (den Dunnen 1996).
Multiexon skipping not only increases the number of
patients that would benefit from this approach but,
more importantly, also decreases its mutation specificity.
The multiexon skipping of exons 45–51 shown in this
study would be frame restoring for 14% of all the de-
letions and 6% of all small mutations reported in the
DMD mutation database (den Dunnen 1996). Further-
more, it offers the therapeutic potential of generating
relatively large in-frame deletions known to be associ-
ated with mild BMD phenotypes (England et al. 1990;
Winnard et al. 1993; Mirabella et al. 1998). Its eventual
therapeutic application will largely depend on the effi-
ciencies in vivo. Lu and colleagues (2003) recently dem-
onstrated AON-induced exon 23–skipping in mdx mus-
cle by using the Pluronic copolymer F127 as a delivery
reagent. Close-to-normal levels of a nearly full-length
dystrophin were observed in many myofibers, which
improved muscle function. Although the effect was op-
timal at 2–4 wk, dystrophin was still detectable at 3 mo
after injection (Lu et al. 2003). In our experience, the
in vitro and in vivo effects of AONs in muscle cells
correlate relatively well, which provides a promising
basis for our current studies on multiexon skipping in
mice.
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